Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Aytu Biopharma (AYTU) over the last 17 years, with Q2 2025 value amounting to $62000.0.

  • Aytu Biopharma's Net Income towards Common Stockholders rose 10500.4% to $62000.0 in Q2 2025 from the same period last year, while for Dec 2025 it was $116000.0, marking a year-over-year increase of 10869.57%. This contributed to the annual value of $620000.0 for FY2025, which is 11865.22% up from last year.
  • As of Q2 2025, Aytu Biopharma's Net Income towards Common Stockholders stood at $62000.0, which was up 10500.4% from $54000.0 recorded in Q1 2025.
  • Aytu Biopharma's Net Income towards Common Stockholders' 5-year high stood at $381000.0 during Q3 2024, with a 5-year trough of -$53.3 million in Q1 2022.
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was -$1.9 million (2023), whereas its average is -$9.6 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first tumbled by 54679.52% in 2021, then skyrocketed by 15888.72% in 2024.
  • Aytu Biopharma's Net Income towards Common Stockholders (Quarter) stood at -$11.5 million in 2021, then soared by 42.04% to -$6.7 million in 2022, then skyrocketed by 87.46% to -$839000.0 in 2023, then soared by 114.66% to $123000.0 in 2024, then tumbled by 49.59% to $62000.0 in 2025.
  • Its Net Income towards Common Stockholders stands at $62000.0 for Q2 2025, versus $54000.0 for Q1 2025 and $123000.0 for Q4 2024.